---
title: "Disc Medicine publishes corporate presentation on hematology pipeline targeting heme, iron pathways"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294368343.md"
description: "Disc Medicine released a corporate presentation detailing its hematology pipeline. Key highlights include the Phase 3 APOLLO trial for bitopertin, an oral GlyT1 inhibitor for erythropoietic protoporphyria, with enrollment completed and topline data expected in Q4 2026. The company also updated its pipeline on iron-regulation antibodies DISC-0974 and DISC-3405 targeting hepcidin pathways for anemia indications."
datetime: "2026-07-30T12:45:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294368343.md)
  - [en](https://longbridge.com/en/news/294368343.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294368343.md)
generator: "portal-rs"
---

# Disc Medicine publishes corporate presentation on hematology pipeline targeting heme, iron pathways

-   Disc Medicine highlighted late-stage development of bitopertin, an oral GlyT1 inhibitor aimed at reducing disease-causing PPIX in erythropoietic protoporphyria. \* Phase 3 APOLLO trial enrollment completed in March 2026; topline data expected in Q4 2026; 183 patients ages 12+ randomized 1:1. \* APOLLO co-primary endpoints: pain-free sunlight exposure time in the final month of treatment; % change in whole-blood metal-free PPIX at 6 months. \* Phase 2 AURORA data cited: 40% reduction in PPIX vs baseline; 75% lower phototoxic reaction rate vs placebo; 86% reported EPP “much better.” \* Pipeline update included iron-regulation antibodies DISC-0974 and DISC-3405 targeting hepcidin pathways for anemia and iron-restriction indications; both remain investigational. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Disc Medicine Inc. i published the original content used to generate this news brief on July 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [IRON.US](https://longbridge.com/en/quote/IRON.US.md)

## Related News & Research

- [Disc Medicine to Present Phase 2 Selcodebart Data in Myelofibrosis Anemia at ASH](https://longbridge.com/en/news/304291082.md)
- [Disc Medicine (IRON) Nails Phase 3 APOLLO Readout, Is The 34% Undervaluation Still Real?](https://longbridge.com/en/news/304497095.md)
- [Disc Medicine's Q3 net loss narrows on lower R&D expenses](https://longbridge.com/en/news/304465929.md)
- [Disc Medicine Participates in Fireside Chats at Investor Conferences](https://longbridge.com/en/news/303964078.md)
- [Disc Medicine highlights bitopertin Phase 3 EPP program in corporate presentation](https://longbridge.com/en/news/298514743.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**